Work

Hybrid synthetic approach and biological characterization of a branched heterodimer for overcoming prostate cancer heterogeneity

Year: 2024

Type: conference-paper

Abstract: Prostate cancer is the fifth cause of cancer-related death in men over the world ( 375 000 cases in 2020) 5-year survival rate of 31% at the late stage.[1]Radiolabelled Prostate-Specific Membrane Antigen (PSMA) inhibitors entry in clinical practice for imaging ([ 68 Ga]Ga-PSMA-11) and therapy ([ 177 Lu]Lu-PSMA-617).[2] 80% of prostate cancers show high heterogeneity low expression of PSMA and presence of multiple distinct tumour foci.[3]

Source: European Peptide Symposium (EPS)

DOI: 10.17952/37eps.2024.p1128

Authors: Santo Previti, Sacha Bodin, Emmanuelle Rémond, Clément Morgat, Florine Cavelier

Institutions: University of Messina, Institut de Neurosciences Cognitives et Intégratives d’Aquitaine, Centre National de la Recherche Scientifique, Institut des Biomolécules Max Mousseron, Centre Hospitalier Universitaire de Bordeaux

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4403085947

FWCI:

Cites:

Cited by:

Related to: 10